Physician profile
Alan B Wiggers
NPI 1629068770
$791.01
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $649 · 2020: $125 · 2022: $17.38.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $187.62 | 2019-2020 | |
| Amgen INC. | $99.05 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $86.66 | 2019 | |
| Sanofi-Aventis U.S. LLC | $76.06 | 2019-2020 | |
| Abbott Laboratories | $70.00 | 2019-2020 | |
| Abbvie INC. | $64.05 | 2019 | |
| Amarin Pharma, INC. | $30.06 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $29.24 | 2019 | |
| Shire North American Group INC | $23.23 | 2019 | |
| Radius Health, INC. | $21.45 | 2019 | |
| Novartis Pharmaceuticals Corporation | $17.38 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $16.78 | 2019 | |
| Arbor Pharmaceuticals, INC. | $16.42 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.81 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $13.80 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.83 | 2020 | |
| Lilly USA, LLC | $11.57 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Wiggers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.